Zeng Ying, Jiang Hongting, Xia Yuting, Wang Zhonglian, Zhang Fei, Luo Cha, Ye Qing, Jian Wei, Zhang Jing, Yang Qingmei, Fu Qiaofen
Department of Radiation Oncology, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming, Yunnan, China.
Departments of Cancer Biotherapy Center, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, Yunnan, China.
Sci Rep. 2025 Jun 4;15(1):19667. doi: 10.1038/s41598-025-04256-1.
To investigate the expression of KRT80 in non-small cell lung cancer (NSCLC) patients and its relationship with clinicopathological factors, prognosis, as well as the differences in KRT80 expression between Xuanwei area and Non-xuanwei area, lung adenocarcinoma and lung squamous cell carcinoma. Based on 178 clinical cases, immunohistochemical methods combined with public databases were used to examine the expression of KRT80 in NSCLC patients and analyze its correlation with various clinicopathological factors and prognosis. The study confirmed the up-regulation of KRT80 expression in NSCLC cancer tissues. Significant regional specific and histological subtype differences in KRT80 expression were revealed. Although the expression level of KRT80 has no direct significant correlation with the prognosis of NSCLC patients, it has a good ability to distinguish cancerous tissue from paracancer tissue. KRT80 can be used as a diagnostic biomarker for NSCLC patients, but its specific mechanism and clinical application value still need to be further explored.
为研究细胞角蛋白80(KRT80)在非小细胞肺癌(NSCLC)患者中的表达情况及其与临床病理因素、预后的关系,以及宣威地区与非宣威地区、肺腺癌与肺鳞癌之间KRT80表达的差异。基于178例临床病例,采用免疫组化方法结合公共数据库检测NSCLC患者中KRT80的表达,并分析其与各种临床病理因素及预后的相关性。研究证实NSCLC癌组织中KRT80表达上调。揭示了KRT80表达存在显著的区域特异性和组织学亚型差异。虽然KRT80的表达水平与NSCLC患者的预后无直接显著相关性,但它具有很好的区分癌组织与癌旁组织的能力。KRT80可作为NSCLC患者的诊断生物标志物,但其具体机制及临床应用价值仍需进一步探索。